Country for PR: United States
Contributor: PR Newswire New York
Friday, July 23 2021 - 05:48
AsiaNet
Texas Cardiac Arrhythmia Institute leader participates in clinical trial for world's first artificial intelligence technology for complex cardiac arrhythmia procedures
AUSTIN, Texas, July 23, 2021 /PRNewswire-AsiaNet/ --

The leader of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's 
Medical Center ( 
https://c212.net/c/link/?t=0&l=en&o=3236884-1&h=4075004528&u=https%3A%2F%2Ftcainstitute.com%2F&a=Texas+Cardiac+Arrhythmia+Institute+(TCAI)+at+St.+David%27s+Medical+Center 
) recently led a clinical study to evaluate the world's first data-driven 
artificial intelligence (AI) platform for cardiac electrophysiology (EP) 
procedures. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac 
electrophysiologist and executive medical director of TCAI, conducted the 
first-in-human trial in Europe.

The NeuTrace EP Platform technology is designed to better guide 
electrophysiologists during complex cardiac EP procedures to help improve 
safety and reduce procedure times.

"This first-of-its-kind innovative AI-driven EP platform allows us to enhance 
ablation by providing advanced metrics and comprehensive patient data in real 
time for a more precise delivery during complex ablation procedures," Dr. 
Natale said. "The AI-guided cardiac mapping technology is designed to provide a 
much safer option for patients and ensure the best possible outcomes."

The EP platform is built on the foundation of an underlying "Data Biome" and 
leverages AI to provide the most high-fidelity signal quality, advanced 
metrics, improved visualizations and comprehensive patient data—including real 
time, electrical signals and 3-D navigation—for a more accurate view of the 
underlying characteristics of the heart during all EP procedures. The mapping 
application is one of several "apps" on the EP platform and is designed to 
provide a more tailored and accurate approach to mapping and ablation, with the 
goal of increasing accuracy and improving patient outcomes—from diagnosis 
through ablation and beyond.

The EP platform aims to assist in the treatment of more than 2.7 million 
patients in the U.S. with atrial fibrillation, in addition to those who require 
ablation procedures. The technology is currently being readied for submission 
to the FDA for marketing authorization.

Media Contact:
Tina Shively
Elizabeth Christian Public Relations
TShively@EChristianPR.com 
+1.845.216.1850 cell

SOURCE: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center
Translations

Japanese